These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 12120041)

  • 1. A phase 2 open trial of pentoxifylline for the treatment of leprosy reactions.
    Dawlah ZM; Cabrera A; Ahern K; Levis WR
    Int J Lepr Other Mycobact Dis; 2002 Mar; 70(1):38-43. PubMed ID: 12120041
    [No Abstract]   [Full Text] [Related]  

  • 2. Is pentoxifylline a viable alternative in the treatment of ENL?
    Sarno EN; Nery JA; Garcia CC; Sampaio EP
    Int J Lepr Other Mycobact Dis; 1995 Dec; 63(4):570-1. PubMed ID: 8642222
    [No Abstract]   [Full Text] [Related]  

  • 3. Leprosy reactions. New knowledge.
    Naafs B
    Trop Geogr Med; 1994; 46(2):80-4. PubMed ID: 8079395
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY; Achirafi A; Flageul B
    Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of IgG subclasses in active and inactive cases in the disease spectrum of leprosy.
    Beuria MK; Parkash O; Joshi B; Mohanty KK; Katoch K; Sengupta U
    Int Arch Allergy Immunol; 1998 Jan; 115(1):61-6. PubMed ID: 9430497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
    Kumar A; Girdhar A; Girdhar BK
    Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral zinc supplementation on the cell mediated immunity in lepromatous leprosy.
    el-Shafei MM; Kamal AA; Soliman H; el Shayeb F; Abdel Baqui MS; Faragalla S; Sabry MK
    J Egypt Public Health Assoc; 1988; 63(5-6):311-36. PubMed ID: 2979949
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of recurrent erythema nodosum leprosum with infliximab.
    Faber WR; Jensema AJ; Goldschmidt WF
    N Engl J Med; 2006 Aug; 355(7):739. PubMed ID: 16914716
    [No Abstract]   [Full Text] [Related]  

  • 9. Relapse in leprosy after multidrug therapy and its differential diagnosis with reversal reaction.
    Reddy PK; Cherian A
    Indian J Lepr; 1991; 63(1):61-9. PubMed ID: 1919091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states.
    Sarno EN; Grau GE; Vieira LM; Nery JA
    Clin Exp Immunol; 1991 Apr; 84(1):103-8. PubMed ID: 2015700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactions in borderline leprosy.
    Ramu G; Desikan KV
    Indian J Lepr; 2002; 74(2):115-28. PubMed ID: 12708730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentoxifylline in the treatment of erythema nodosum leprosum.
    De Carsalade GY; Achirafi A; Flageul B
    J Dermatol; 2003 Jan; 30(1):64-8. PubMed ID: 12598712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients.
    Arunthathi S; Ebenezer L; Kumuda C
    Lepr Rev; 1998 Jun; 69(2):173-7. PubMed ID: 9715603
    [No Abstract]   [Full Text] [Related]  

  • 14. Pentoxifylline may be useful in the treatment of type 2 leprosy reaction.
    Talhari S; Orsi AT; Talhari AC; Souza FH; Ferreira LC
    Lepr Rev; 1995 Sep; 66(3):261-3. PubMed ID: 7500827
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor necrosis factor: status in reactions in leprosy before and after treatment.
    Bhattacharya SN; Chattopadhaya D; Saha K
    Int J Dermatol; 1993 Jun; 32(6):436-9. PubMed ID: 8320025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL.
    Moreira AL; Kaplan G; Villahermosa LG; Fajardo TJ; Abalos RM; Cellona RV; Balagon MV; Tan EV; Walsh GP
    Int J Lepr Other Mycobact Dis; 1998 Mar; 66(1):61-5. PubMed ID: 9614845
    [No Abstract]   [Full Text] [Related]  

  • 17. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
    Rea TH; Sieling PA
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic characteristics of leprosy reactions.
    Scollard DM; Smith T; Bhoopat L; Theetranont C; Rangdaeng S; Morens DM
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampicin-induced erythema nodosum leprosum-like eruption in borderline lepromatous leprosy.
    Karthikeyan K; Thappa DM; Kadhiravan T
    Indian J Lepr; 2001; 73(2):167-9. PubMed ID: 11579653
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of mycophenolate mofetil in the treatment of leprosy reactions.
    Burdick AE; Ramirez CC
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):127-8. PubMed ID: 16830656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.